https://www.clinicaltrialsarena.com/news/mirvetuximab-soravtansine-ovarian-cancer-data/
ImmunoGen mirvetuximab soravtansine fails Phase III ovarian cancer trial
Aug 9, 2019 - ImmunoGen has reported negative top-line results from the Phase III FORWARD I ovarian cancer trial of mirvetuximab soravtansine.
mirvetuximab soravtansinephase iiiovarian cancerimmunogenfails
https://www.biospace.com/immunogen-named-one-of-the-b-boston-globe-s-b-top-places-to-work-for-third-consecutive-year
ImmunoGen Named One Of The Boston Globe's Top Places To Work For Third Consecutive Year - BioSpace
the boston globeimmunogennamedonetop
https://www.salesandmarketingnetwork.com/news_release_bs.html?pipe=0000ac177000191&ID=2037360&key=Roche+Group
News for Medical Sales Reps: ImmunoGen, Inc. Announces Executive Change
sales repsnewsmedicalimmunogeninc
https://www.pricetargets.com/NASDAQ/IMGN/
IMGN Stock Price Target | ImmunoGen Analyst Ratings
Where is ImmunoGen stock heading? Wall Street analysts weigh in with their latest ratings and IMGN price targets at PriceTargets.com.
stock priceimgntargetimmunogenanalyst
https://news.abbvie.com/2018-10-08-ImmunoGen-to-Present-Initial-Data-from-FORWARD-II-Expansion-Cohort-of-Mirvetuximab-Soravtansine-in-Combination-with-KEYTRUDA-at-ESMO
ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in...
mirvetuximab soravtansineimmunogenpresentinitialdata
https://www.businesswire.com/news/home/20231101753557/en/ImmunoGen-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
immunogenannouncesinducementgrantsnasdaq